- Home
- GDS vs AXSM Comparison
GDS vs AXSM Comparison
Compare GDS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDS
- AXSM
- Stock Information
- Founded
- GDS 2001
- AXSM 2012
- Country
- GDS China
- AXSM United States
- Employees
- GDS N/A
- AXSM N/A
- Industry
- GDS Computer Software: Programming Data Processing
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- GDS Technology
- AXSM Health Care
- Exchange
- GDS Nasdaq
- AXSM Nasdaq
- Market Cap
- GDS 3.8B
- AXSM 4.2B
- IPO Year
- GDS 2016
- AXSM 2015
- Fundamental
- Price
- GDS $22.86
- AXSM $96.18
- Analyst Decision
- GDS Buy
- AXSM Strong Buy
- Analyst Count
- GDS 3
- AXSM 13
- Target Price
- GDS $18.47
- AXSM $130.69
- AVG Volume (30 Days)
- GDS 1.4M
- AXSM 965.3K
- Earning Date
- GDS 11-19-2024
- AXSM 02-18-2025
- Dividend Yield
- GDS N/A
- AXSM N/A
- EPS Growth
- GDS N/A
- AXSM N/A
- EPS
- GDS N/A
- AXSM N/A
- Revenue
- GDS $1,564,750,016.00
- AXSM $338,457,000.00
- Revenue This Year
- GDS $18.41
- AXSM $44.77
- Revenue Next Year
- GDS $18.73
- AXSM $67.70
- P/E Ratio
- GDS N/A
- AXSM N/A
- Revenue Growth
- GDS 11.95
- AXSM 51.47
- 52 Week Low
- GDS $5.01
- AXSM $64.11
- 52 Week High
- GDS $29.17
- AXSM $105.00
- Technical
- Relative Strength Index (RSI)
- GDS 50.86
- AXSM 59.04
- Support Level
- GDS $21.15
- AXSM $91.81
- Resistance Level
- GDS $24.08
- AXSM $95.36
- Average True Range (ATR)
- GDS 1.69
- AXSM 4.95
- MACD
- GDS -0.23
- AXSM 1.43
- Stochastic Oscillator
- GDS 21.26
- AXSM 89.89
About GDS GDS Holdings Limited ADS
GDS Holdings started as an IT service provider in 2001 then moved to the data center business with its first self-developed data center opening in 2010. The company now develops and operates data centers in China and also builds, operates and transfers data centers for other clients. It offers colocation and managed services and mainly targets hyperscale cloud service customers who take large areas of its data centers or even whole data centers under long-term contracts. It has aggressively raised capital over the past four years for expansion. Its data centers are located predominantly in and around the Tier 1 cities in China and it has also started an expanding into Southeast Asia. GDS listed on the Nasdaq in 2016 and completed a secondary listing in Hong Kong in 2020.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.